Clinical Trial Update: Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Daclatasvir in Treatment-Naїve Patients With Chronic Hepatitis C Genotype 1b [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating an all-oral combination of Narlaprevir/Ritonavir and Daclatasvir for treatment-naïve patients with chronic hepatitis C genotyp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Daclatasvir (daclatasvir)
• Narlaprevir/Ritonavir

Snippet

Sponsor: R-Pharm | Conditions: Chronic Hepatitis C Genotype 1b | Phase 2 | Status: COMPLETED